{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:37:49Z","timestamp":1793119069920,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bbmt.2020.03.005","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T14:04:37Z","timestamp":1584367477000},"page":"1711-1718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-0275","authenticated-orcid":false,"given":"David","family":"Kliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Nivison-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kerridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Purtill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Szer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.03.005_bib0001","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0002","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million haemopoietic stem-cell transplants: a retrospective observational study","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0003","unstructured":"D'Souza A, Fretham C.Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides, 2018. Available at:https:\/\/www.cibmtr.org\/. Accessed 1st April 2019"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0004","unstructured":"Australasian Bone Marrow Transplant Recipient Registry. Australasian Bone Marrow Transplant Recipient Registry: annual data summary 2017. www.abmtrr.org. Accessed 24th Jan 2019"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0005","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bbmt.2015.09.009","article-title":"A review of hematopoietic cell transplantation in Australia and New Zealand, 2005 to 2013","volume":"22","author":"Nivison-Smith","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0006","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","article-title":"Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors","volume":"31","author":"Hahn","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0007","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/cncr.31114","article-title":"Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma","volume":"124","author":"Myers","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0008","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2012.311","article-title":"Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies","volume":"27","author":"Vanderwalde","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0009","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0010","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.bbmt.2016.05.019","article-title":"Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation","volume":"22","author":"Atsuta","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0011","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0012","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0013","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bbmt.2009.06.014","article-title":"Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates","volume":"15","author":"Nivison-Smith","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0014","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bbmt.2005.11.518","article-title":"Long-term survival after blood and marrow transplantation: comparison with an age-and gender-matched normative population","volume":"12","author":"Pond","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry","volume":"341","author":"Soci\u00e9","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0016","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0017","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbmt.2011.12.519","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"18","author":"Majhail","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0018","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbmt.2014.06.035","article-title":"Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors","volume":"21","author":"Hashmi","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0019","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2017-03-725671","article-title":"How I monitor long-term and late effects after blood or marrow transplantation","volume":"130","author":"Bhatia","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003\u20132007 versus 2013\u20132017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2796.2006.01677.x","article-title":"Interpreting trends in cancer patient survival","volume":"260","author":"Dickman","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0022","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/sim.1597","article-title":"Regression models for relative survival","volume":"23","author":"Dickman","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0023","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/biostatistics\/kxl030","article-title":"Estimating and modeling the cure fraction in population-based cancer survival analysis","volume":"8","author":"Lambert","year":"2007","journal-title":"Biostatistics"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0024","unstructured":"University of California Berkeley and Max Planck Institute for Demographic Research. Human mortality database. Available at: www.mortality.org. Accessed 1st Nov 2017"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0025","unstructured":"Australian Bureau of Statistics. Life tables, states, territories and Australia. www.abs.gov.au. Accessed 13th Nov 2017"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0026","unstructured":"Statistics New Zealand. New Zealand life tables 2000-2016. Available at:www.stats.govt.nz. Accessed 1st August 2018"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0027","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41409-017-0076-2","article-title":"Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients","volume":"53","author":"Solh","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0028","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0029","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.bbmt.2016.04.006","article-title":"Factors predicting graft-versus-host disease\u2013free, relapse-free survival after allogeneic hematopoietic cell transplantation: multivariable analysis from a single center","volume":"22","author":"Solh","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0030","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0031","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"22","author":"Moiseev","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0032","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kroger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0033","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti\u2013t-lymphocyte globulin to assess impact on chronic graft-versus-host disease\u2013free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0034","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0035","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2013.07.020","article-title":"Prevalence of hematopoietic cell transplant survivors in the United States","volume":"19","author":"Majhail","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0036","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbmt.2017.09.011","article-title":"Activity and capacity profile of transplant physicians and centers in Australia and New Zealand","volume":"24","author":"Nivison-Smith","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.03.005_bib0037","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2016.10.020","article-title":"National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: developing recommendations to improve survivorship and long-term outcomes","volume":"23","author":"Battiwalla","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120301427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120301427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:11:23Z","timestamp":1761059483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120301427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1083879120301427"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy","name":"copyright","label":"Copyright"}]}}